Oli Denne

Oli is a senior associate in our Cambridge office and is part of the Corporate Technology team.

Oli advises a range of companies in the tech and life sciences sectors on a variety of corporate matters, including venture capital investments, fundraisings, M&A and joint ventures.

CV

Since 2023 Senior Associate, Taylor Wessing

2021 - 2023 Associate, Taylor Wessing

2019 - 2020 Associate, Slaughter and May

Carrière

Since 2023 Senior Associate, Taylor Wessing

2021 - 2023 Associate, Taylor Wessing

2019 - 2020 Associate, Slaughter and May

Formation

2019 Admitted as a solicitor in England & Wales

2016 - 2017 GDL & LPC, BPP Law School

2012 - 2015 BA Politics, University of Warwick

Experience

Apollo Therapeutics closes $226.5 million series C financing

We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.

Press release

Actualités et publications récentes

View Oli's insights

Cliquer ici pour en savoir plus

Fusions et acquisitions d’entreprises et marchés financiers internationaux

Advising personal care brand, Wild, on its acquisition by Unilever

1 avril 2025

par Ed Chapman et Oli Denne

Fusions et acquisitions d’entreprises et marchés financiers internationaux

Shift Bioscience raises US$16 million seed funding

21 octobre 2024

par Ross McNaughton et Oli Denne

Cliquer ici pour en savoir plus

Fusions et acquisitions d’entreprises et marchés financiers internationaux

Advising Nuclera on its US$75 million series C financing

16 octobre 2024

par plusieurs auteurs

Cliquer ici pour en savoir plus

	
		OSZAR »